Vedolizumab Quantitation with Antibodies, Serum
Use
This test is useful for assessing primary or secondary loss of response to vedolizumab therapy and aids in achieving desired serum concentrations. Vedolizumab is a monoclonal antibody targeting integrin alpha-4 beta-7, approved for treating adults with moderately to severely active ulcerative colitis or Crohn's disease. Monitoring for proactive and reactive approaches helps manage therapy effectively, though optimal therapeutic thresholds are not yet established.
Special Instructions
Not provided.
Limitations
The test's accuracy can be compromised if nivolumab is used concurrently, requiring a wait of four weeks post-treatment before testing. High concentrations of vedolizumab may affect the accuracy of antibody detection. Results should be interpreted in the clinical context as high biotin levels could interfere with the antibody assay. Current guidelines on the optimal concentration thresholds are lacking.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 90794-9 - Vedol + Vedol Ab Pnl SerPl-mCnc
- 90805-3 - Vedolizumab Trough SerPl LC/MS/MS-mCnc
- 86899-2 - Vedolizumab Ab SerPl IA-mCnc
- 59462-2 - Clinical biochemist review
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
0.3 mL
Container
Plastic vial
Collection Instructions
Draw blood immediately before the next scheduled dose (trough specimen). Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.
Patient Preparation
Avoid biotin supplements for 12 hours before collection. Discontinue nivolumab 4 weeks prior to testing.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 28 days |
| Frozen | 28 days |